Salvador Sabino Mojarro-Bazán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Salvador Sabino Mojarro-Bazán has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Abel Requena-Rivera
Centro de Estudios de Investigación Metabólicos y Cardiovasculares S.C., Área de Investigación. Ciudad Madero, Tamaulipas, México
1 shared publication - Norma Lidia Fernández-Ordóñez
Hospital Regional Pemex, Minatitlán, Veracruz, México
1 shared publication - Rafael Violante-Ortiz
Facultad de Medicina de Tampico "Dr. Alberto Romo Caballero", Universidad Autónoma de Tamaulipas (UAT), Tampico, Tamaulipas, México
1 shared publication - Tania Alemán-Cabrera
Instituto Mexicano del Seguro Social, Hospital General Regional No. 6 "Lic. Ignacio García Téllez", Área de Ginecología y Obstetricia. Ciudad Madero, Tamaulipas, México
1 shared publication
Latest Publications
- Open Access
- 2 January 2023
- Vol. 61 (1) , 61-67
[Maternal-fetal outcomes in women with gestational diabetes in an intensive control program].
Gestational diabetes mellitus (GDM) is first diagnosed during pregnancy and it is the most frequent maternal hyperglycemia. To know fetal and maternal outcomes in an intensive control program in pregnant women with and without DMG at the Instituto Mexicano del Seguro Social (Mexican Institute for Social Security) Regional General Hospital No. 6, in Ciudad Madero, Tamaulipas. A descriptive and retrospective study, which included 800 outcomes of pregnant women between January 2009 and June 2020. Anthropometric data and pregnancy outcomes were collected. The intensive control program consisted of face-to-face consultations of 1 to 4 weeks, granted according to the degree of metabolic control, with which it was given nutritional counseling, recommendations for physical activity, and in some cases pharmacological treatment. The prevalence of GDM was 36.2%. There were no statistically significant differences between the two groups, except for respiratory distress syndrome, which was more common in GDM (9.4%, p = 0.06). Patients with GDM had a lower prevalence of macrosomy (6.1%) compared to the control group (6.6%). All women admitted to the program in the first trimester had fewer fetal and maternal complications. This study demonstrates the effectiveness and efficiency of implementing an intensive control program in women with GDM, by reducing and equalizing maternal and fetal outcomes compared to a group of women without the disease.
- 2 January 2023
- Vol. 61 (1) , 61-67
Open Access[Maternal-fetal outcomes in women with gestational diabetes in an intensive control program].
Gestational diabetes mellitus (GDM) is first diagnosed during pregnancy and it is the most frequent maternal hyperglycemia. To know fetal and maternal outcomes in an intensive control program in pregnant women with and without DMG at the Instituto Mexicano del Seguro Social (Mexican Institute for Social Security) Regional General Hospital No. 6, in Ciudad Madero, Tamaulipas. A descriptive and retrospective study, which included 800 outcomes of pregnant women between January 2009 and June 2020. Anthropometric data and pregnancy outcomes were collected. The intensive control program consisted of face-to-face consultations of 1 to 4 weeks, granted according to the degree of metabolic control, with which it was given nutritional counseling, recommendations for physical activity, and in some cases pharmacological treatment. The prevalence of GDM was 36.2%. There were no statistically significant differences between the two groups, except for respiratory distress syndrome, which was more common in GDM (9.4%, p = 0.06). Patients with GDM had a lower prevalence of macrosomy (6.1%) compared to the control group (6.6%). All women admitted to the program in the first trimester had fewer fetal and maternal complications. This study demonstrates the effectiveness and efficiency of implementing an intensive control program in women with GDM, by reducing and equalizing maternal and fetal outcomes compared to a group of women without the disease.